FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC

FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC

Lung Cancer Considered

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on the FLAURA2 study and changes in the first line treatment of EGFR NSCLC with guests Dr. Pasi Jänne and Dr. Marcelo Corassa. FLAURA2…

Related tracks